Ticker: QURE

uniQure (QURE) jumps ~150% after Phase I/II AMT‑130 topline in Huntington's - high‑dose showed 75% cUHDRS slowing at 36 months. BLA targeted Q1 2026; regulatory runway and technical hurdles now drive volatility and re‑rating.

uniQure N.V. (NASDAQ: QURE) has recently published its financial report for the second quarter of 2025, revealing both advancements and challenges in its operations. Key Highlights from the Income Statement: Total Revenues: $5.3 million for Q2 2025, down from $11.1 million in Q2 2024. License Re...

uniQure N.V. (NASDAQ: QURE) has recently reported its financial results for the first quarter of 2025, revealing significant challenges and opportunities regarding its operations in gene therapy. Key Points from the Income Statement: Total Revenues: $1.57 million in Q1 2025, down from $8.49 mill...